With the roll-out of Clozaril, in 1989, with its promise to treat recalcitrant schizophrenics, the era of the second-generation, or ‘atypical,’ antipsychotics, was born. And there is much the atypicals offer over the first-generation antipsychotics, including freedom from fear from the worst side effects: tardive dyskinesia, with its uncontrolled involuntary movements, uncontrollable tremors, akathisia, with its inability to [...]

read more: Diabetes Drug Or Dieter’s Dream? Metformin and Antipsychotic-Induced Weight Gain